

FORM 5A

ANNUAL LISTING SUMMARY

Introduction

The requirement to file this Form 5A does not apply to NV Issuers. NV Issuers must file a Form 51-102F2 Annual Information Form.

This Annual Listing Summary must be posted on or before the day on which the Issuer's annual financial statements are to be filed under the Securities Act. This statement is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by the Exchange Policies.

General Instructions

- (a) Prepare this Annual Listing Summary using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the following items must be in narrative form. When the answer to any item is negative or not applicable to the Issuer, state it in a sentence. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Listed Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Listed Issuer Name: MYNDTEC INC.

Website: <https://myndtec.com/>

Listing Statement Date: February 16, 2022

Description(s) of listed securities(symbol/type): MYTC/Common Shares

Brief Description of the Issuer's Business: MyndTec is a Canadian medical technology company dedicated to the development and commercialization of innovative products that improve function, maximize independence and enhance the quality of life for individuals who have suffered injury to the central nervous system as a result of stroke, spinal cord injury and certain traumatic brain injuries.

Description of additional (unlisted) securities outstanding:
Options – NA

Jurisdiction of Incorporation: Ontario		
Fiscal Year End: December 31		
Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled): June 15, 2023/June 18, 2024		
Financial Information as at: December 31, 2023		
	Current	Previous
Cash	\$187,411	\$68,621
Current Assets	\$436,009	\$402,545
Non-current Assets	\$118,839	\$240,024
Current Liabilities	\$1,440,628	\$1,270,425
Non-current Liabilities	\$34,000	\$297,483
Shareholders' equity	\$(919,780)	\$(925,339)
Revenue	\$ 137,312	\$ 255,801
Net Income	\$(1,723,330)	\$(2,132,213)
Net Cash Flow from Operations	\$(976,907)	\$(2,343,697)

SUPPLEMENTARY INFORMATION

The supplementary information set out below must be provided when not included in the Schedules. If the required details are included in Schedule A or B, provide specific reference to the page or note.

1. Related party transactions

Provide disclosure of all transactions with a Related Person, including those previously disclosed on Form 10. Include in the disclosure the following information about the transactions with Related Persons:

- (a) A description of the relationship between the transacting parties. Be as precise as possible in this description of the relationship. Terms such as affiliate, associate or related company without further clarifying details are not sufficient.
- (b) A description of the transaction(s), including those for which no amount has been recorded.
- (c) The recorded amount of the transactions classified by financial statement category.

- (d) The amounts due to or from Related Persons and the terms and conditions relating thereto.
- (e) Contractual obligations with Related Persons, separate from other contractual obligations.
- (f) Contingencies involving Related Persons, separate from other contingencies.

The related party transactions are included in Note 13 to the audited consolidated financial statements which are attached hereto as "Schedule – A".

2. Summary of securities issued and options granted during the period.

Provide the following information for the Listed Issuer's fiscal year:

- (a) summary of securities issued during the period,

The summary of securities issued during the reporting period is included in Note 14 to the audited consolidated financial statements which are attached hereto as "Schedule – A".

- (b) summary of options granted during the period,

The summary of options granted during the reporting period is included in Note 14 to the audited consolidated financial statements which are attached hereto as "Schedule – A".

3. Summary of securities as at the end of the reporting period.

Provide the following information in tabular format as at the end of the reporting period:

- (a) description of authorized share capital including number of securities outstanding for each class, dividend rates on preferred shares and whether or not cumulative, redemption and conversion provisions,
- (b) description of options, warrants and convertible securities outstanding, including number or amount, exercise or conversion price and expiry date, and any recorded value, and
- (b) number of shares in each class of shares subject to escrow or pooling agreements or any other restriction on transfer.

The summary of securities as at the end of the reporting period is included in Note 14 to the audited consolidated financial statements which are attached hereto as "Schedule – A".

4. List the names of the directors and officers and include the position(s) held and the date of appointment, as at the date this report is signed and filed.

Craig Leon	Chief Executive Officer and Director	June 23, 2021
Harvey Griggs	Director	May 13, 2019
Milos R. Popovic	Chairman	June 10, 2008
Richard Dick Widgren	Director	December 28, 2015
William Jackson	Director	May 11, 2022
Scott Franklin	Chief Financial Officer	June 15, 2021
Monique Hutchins	Corporate Secretary	April 14, 2022

5. **Financial Resources**

- a) State the business objectives that the Issuer expects to accomplish in the forthcoming 12-month period;
- b) Describe each significant event or milestone that must occur for the business objectives in (a) to be accomplished and state the specific time period in which each event is expected to occur and the costs related to each event;
- c) Disclose the total funds available to the Issuer and the following breakdown of those funds:
 - (i) the estimated consolidated working capital (deficiency) as of the most recent month end prior to filing the Listing Statement, and
 - (ii) the total other funds, and the sources of such funds, available to be used to achieve the objectives and milestones set out in paragraphs (a) and (b); and
 - (iii) describe in reasonable detail and, if appropriate, using tabular form, each of the principal purposes, with approximate amounts, for which the funds available described under the preceding paragraph will be used by the Issuer.

By investing in research and development efforts to enhance its existing products, exploring new applications of Functional Electrical Stimulation (FES), and driving technological innovation in the field of neurology, the Company is seeking to leverage its existing knowledge base to expand its product portfolio by identifying related and new medical technologies that leverage FES to target neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). In connection with this, the Company may seek clinical validation by conducting rigorous clinical trials to demonstrate the safety, efficacy, and clinical benefits of our existing and new technologies across

a range of neurological disorders. The Company may also seek to obtain further regulatory authorizations (e.g. FDA clearance, CE marking) for its medical technologies in key markets to ensure market access and commercialization.

Please see the Issuer's Financial Statements for the year ended December 31, 2023, attached as Schedule A and the corresponding Management Discussion and Analysis attached as Schedule B. The Company has accumulated \$19,678,766 of losses as at December 31, 2023, and its ability to continue as a going concern is dependent on it raising future required capital; bringing its products to market; and, achieving and maintaining profitable operations.

6. Status of Operations

During the fiscal year, did the Listed Issuer

- (a) reduce or impair its principal operating assets; or
- (b) cease or substantively reduce its business operations with respect to its stated business objectives in the most recent Listing Statement?

Provide details:

7. Business Activity

a) Activity for a mining or oil and gas Listed Issuer

- (i) For the most recent fiscal year, did the Listed Issuer have positive cash flow, significant revenue from operations, or \$50,000 in exploration or development expenditures?

Provide details. N/A

- (ii) If the response to (i) above is "no", for the three most recent fiscal years did the Listed Issuer have an aggregate of \$100,000 in exploration or development expenditures?

Provide details. N/A

b) Activity for industry segments other than mining or oil & gas

- (i) For the most recent fiscal year, did the Listed Issuer have positive cash flow, or \$100,000 in revenue from operations or \$100,000 in development expenditures?

The issuer recorded more than \$100,000 in revenue from operations.

- (ii) If the response to (i) above is "no", for the three most recent fiscal years, did the Listed Issuer have either \$200,000 in operating revenues or \$200,000 in expenditures directly related to the development of the business?

Provide details. N/A

SCHEDULE A: AUDITED ANNUAL FINANCIAL STATEMENTS

SCHEDULE B: MANAGEMENT DISCUSSION AND ANALYSIS

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Annual Listing Summary.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 5 Quarterly Listing Statement is true.

Dated May 1, 2024.

Craig Leon

Name of Director or Senior Officer

/s/ "Craig Leon"

Signature

Chief Executive Officer

Official Capacity

Issuer Details Name of Issuer MyndTec Inc.	For Year End December 31, 2023	Date of Report YY/MM/DD 2024/05/01
Issuer Address 1900Minnesota Court Suite 122		
City/Province/Postal Code Mississauga, Ontario L5N 3C9	Issuer Fax No.	Issuer Telephone No. 416-569-0430
Contact Name Craig Leon	Contact Position CEO	Contact Telephone No. 416-569-0430
Contact Email Address Craig.leon@myndtec.com	Web Site Address www.myndtec.com	